version: "1.0.0" name: target-disease-research description: Use when researching a biomedical target and disease relationship, mechanism, human evidence, clinical translation, safety, failed programs, competitive trials, or an auditable pharmaceutical decision dossier.

Target-Disease Research

This workflow supports pharmaceutical research and portfolio decisions. It does not diagnose a patient, select treatment, or assert that a new drug was created.

1. Require a target and disease. Capture aliases, population or subtype, date

bounds, intervention class, exclusions, decision question, and output language when supplied.

1. Stop if the request contains patient-identifying information and ask for a

de-identified research question.

1. Reuse only the project-resolution part of argus-run: call

argus_project_list for the exact work directory, then reuse that project or call argus_project_create. Do not dispatch while resolving the project.

1. Call argus_message exactly once with an objective that asks Manager to

select the built-in medical vertical and to produce: medical/evidence.jsonl, medical/evidence_matrix.csv, medical/target_disease_memo.md, and medical/review.json.

1. Require source IDs and URLs, exact retrieval/query provenance, conflicts,

failures, missing fields, and a separate infrastructure-failure count.

1. Treat PubMed metadata as metadata, not full-text verification. Treat trial

registration as trial existence/design, not evidence of efficacy. Qualify cross-trial comparisons unless population, endpoint, comparator, follow-up, treatment line, and data cutoff align.

1. Return the project ID. Use argus-status for later progress or artifact

inspection instead of polling in the same turn.

Only describe a dossier as reviewed when Argus returns a Reviewer-certified state. Preserve negative and contradictory evidence.